Antigen Ligation Triggers a Conformational Change within the Constant Domain of the αβ T Cell Receptor  by Beddoe, Travis et al.
Immunity
ArticleAntigen Ligation Triggers a Conformational Change
within the Constant Domain of the ab T Cell Receptor
Travis Beddoe,1 Zhenjun Chen,2 Craig S. Clements,1 Lauren K. Ely,1 Simon R. Bushell,1 Julian P. Vivian,1
Lars Kjer-Nielsen,2 Siew Siew Pang,1 Michelle A. Dunstone,1 Yu Chih Liu,1 Whitney A. Macdonald,1
Matthew A. Perugini,3 Matthew C.J. Wilce,1 Scott R. Burrows,4 Anthony W. Purcell,3 Tony Tiganis,1
Stephen P. Bottomley,1 James McCluskey,2,5,* and Jamie Rossjohn1,5,*
1Protein Crystallography Unit, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences,
Monash University, Clayton, Victoria 3800, Australia
2Department of Microbiology and Immunology
3Department of Biochemistry and Molecular Biology, The Bio21 Molecular Science and Biotechnology Institute
University of Melbourne, Parkville, Victoria 3010, Australia
4Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Brisbane 4029, Australia
5These authors contributed equally to this work
*Correspondence: jamesm1@unimelb.edu.au (J.M.), jamie.rossjohn@med.monash.edu.au (J.R.)
DOI 10.1016/j.immuni.2009.03.018SUMMARY
Ligation of the ab T cell receptor (TCR) by a specific
peptide-loaded major histocompatibility complex
(pMHC) molecule initiates T cell signaling via the
CD3 complex. However, the initial events that link
antigen recognition to T cell signal transduction
remain unclear. Here we show, via fluorescence-
based experiments and structural analyses, that
MHC-restricted antigen recognition by the ab TCR
results in a specific conformational change confined
to the A-B loop within the a chain of the constant
domain (Ca). The apparent affinity constant of this
A-B loop movement mirrored that of ab TCR-pMHC
ligation and was observed in two ab TCRs with
distinct pMHC specificities. The Ag-induced A-B
loop conformational change could be inhibited by
fixing the juxtapositioning of the constant domains
andwas shown to be reversible upon pMHCdisasso-
ciation. Notably, the loop movement within the Ca
domain, although specific for an agonist pMHC
ligand, was not observed with a pMHC antagonist.
Moreover, mutagenesis of residues within the A-B
loop impaired T cell signaling in an in vitro system
of antigen-specific TCR stimulation. Collectively,
our findings provide a basis for the earliest molecular
events that underlie Ag-induced T cell triggering.
INTRODUCTION
T cells orchestrate specific immunity through antigen (Ag) recog-
nition via specific ab or gd T cell receptors (TCRs). The majority
of T cells express an ab TCR that recognizes peptide-laden
major histocompatibility complex (pMHC) class I and class II
molecules (Rudolph et al., 2006), whereas natural killer T cells
(NKT cells) express a semi-invariant ab TCR that interacts with
lipid-laden CD1d molecules (Borg et al., 2007). MHC-restrictedTCR ligation is central to the adaptive immune response and
results in a signal being transmitted to the T cell that activates
a program of effector function and proliferative expansion of
Ag-specific, naive T cells. Each chain of the ab TCR heterodimer
is composed of a variable (V) and a constant (C) ectodomain.
The V domains, which interact with Ag via the complementarity
determining regions (CDRs), show considerable diversity
(Turner et al., 2006), and this is manifested in the different modes
of interaction between TCRs and pMHC ligands, notwith-
standing some generalities in TCR-pMHC docking (Clements
et al., 2006; Feng et al., 2007; Rudolph et al., 2006; Tynan
et al., 2005).
Despite these diverse TCR-pMHC structural landscapes, Ag
ligation leads to T cell signaling, yet the TCR does not possess
intracellular signaling domains, and as such antigen recognition
is disassociated from T cell signaling. Instead, the ab and gd
TCRs are noncovalently coupled to the conserved multisubunit
signaling apparatus, comprising the CD33g and CD33d hetero-
dimers and the zz homodimer (Kane et al., 2000). Although the
TCR-CD3 interactions are mediated via their respective trans-
membrane regions, the interactions between their ectodomains
are considered to contribute to TCR-CD3 specificity (Call and
Wucherpfennig, 2004, 2005; Call et al., 2004). In mice and hu-
mans, it appears that the dominant stoichiometry of the complex
comprises one ab TCR, one CD33g heterodimer, one CD33d het-
erodimer, and one zz homodimer although higher-order stoichi-
ometries are also reported in T cells (Schamel et al., 2005), and
moreover the stoichiometry differs in gd TCR-CD3 complexes
(Hayes and Love, 2006). Although structures of isolated CD3
components have been determined (Arnett et al., 2004; Kjer-
Nielsen et al., 2004; Sun et al., 2001, 2004), the precise nature
of the interaction between the TCR and the CD3 complex is
unknown, although it is clear that the monomorphic CD3
subunits interact with the constant and transmembrane domains
of the TCR (Call et al., 2004; Kuhns and Davis, 2007). Moreover,
different schemes have been proposed to explain the mecha-
nism by which TCR ligation is directly communicated to the
signaling apparatus. The current dogma favors amodel whereby
clustering of TCRs concentrates the signaling units and associ-
ated kinases to achieve a threshold of signaling via receptorImmunity 30, 777–788, June 19, 2009 ª2009 Elsevier Inc. 777
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Nonetheless, there is also tantalizing evidence that the earliest
TCR signaling event involves binding of the adaptor protein
Nck to a proline-rich region in the cytoplasmic tail of CD33 that
is exposed by a change in the TCR-CD3 conformation (Alarcon
et al., 2006; Choudhuri et al., 2005). Moreover, a role for the
proline-rich region in the CD4+CD8+ developmental stage has
recently been reported (Mingueneau et al., 2008). However,
evidence for a conformationally transmitted signal through the
TCR ectodomains remains elusive, not the least because of
the inherent challenge of unambiguously demonstrating a link
between any conformational change in the TCR and subsequent
signaling. This is especially difficult given the likely role of TCR
aggregation regardless of the earliest signaling event. Accord-
ingly, a key step in making a connection between any conforma-
tional change and signaling is the demonstration of a dynamic,
ligand-induced conformational change in a region of the TCR
likely to impact on CD3 structure in the manner described by
Alarcon and colleagues (Gil et al., 2002, 2005; Minguet et al.,
2007; Risueno et al., 2005).
Fluorescence-based approaches for detecting real-time
conformational change in proteins are a well-established tech-
nique (Cohen et al., 2005; Johnson, 2005; Kobilka and Gether,
2002) and moreover represent the most sensitive spectroscopic
technique available because it requires small amounts of
sample yet produces a high signal to noise ratio even in
complex mixtures. In addition there are many commercial
fluorophores available that have unique chemical properties,
which can be used to measure conformational change. To
address the central question of whether Ag-induced conforma-
tional change within the ectodomain of a TCR underscores the
basis of T cell triggering, we adopted a site-directed fluores-
cence labeling (SDFL) approach, whereby we engineered
unique cysteine residues into the TCR and specifically labeled
the TCR with a thiol-reactive fluorescent dye. Collectively, our
studies demonstrate that pMHC ligation leads to a specific
conformational change within the constant domain of the
TCR, suggesting a basis for the earliest molecular events that
underlie T cell triggering.
RESULTS
Structural Data
Intracellular signaling via cell surface receptors can proceed by
a number of distinct mechanisms, which include ligand-induced
oligomerization, higher-order aggregation, and induced confor-
mational changes. Much like immunoglobulin ligation on B cells,
the initial structural data on TCR-pMHC complexes suggested
no conformational change within the TCR C domain upon Ag
ligation, and as such T cell-triggering models that invoked
a conformational change in the TCR upon Ag ligation were dis-
counted; however, this initial evidence relied on very few TCRs
for which unliganded and ligated structures could be directly
compared. Moreover, the relatively low resolution of TCR-
pMHC complexes, crystal-packing effects, the poorly resolved
electron density of the C domains in some TCR-pMHC
complexes, and the large number of TCR-pMHC complexes
determined in which the C domains were absent (Rudolph
et al., 2006) could have masked any conformational changes778 Immunity 30, 777–788, June 19, 2009 ª2009 Elsevier Inc.within the constant domain. Given that the TCR structural data-
base is nowmore extensive (Table S1 available online; Clements
et al., 2006; Godfrey et al., 2008; Gras et al., 2008), we re-evalu-
ated this initial contention. Analysis of the structural data of
unliganded and ligated ab TCRs suggests the propensity for
the A-B loop (residues 129 to 136) of the Ca domain to exist in
two conformational states that are correlated with the ligation
state of the TCR.Moreover, these differing conformational states
of the A-B loop have been observed in ab TCRs interacting with
pMHC-I, pMHC-II, and CD1d-lipid complexes (Supplemental
Data). This conformational change was observed in the well-
described LC13 TCR system where the A-B loop points toward
the Cb b sheet in the unliganded state and appears to represent
a ‘‘closed’’ conformation whereas upon ligation with HLA-B8-
FLRGRAYGL (HLA-B8FLR), the A-B loop adopts an ‘‘open’’
conformation in that it moves away from the Cb domain (Figures
1A–1D; Kjer-Nielsen et al., 2002a). The A-B loop, which is rich in
positively charged residues, projects into a cavity of the Cb
domain and was initially proposed as a binding site for the nega-
tively charged CD33g (Ghendler et al., 1998; Wang et al., 1998).
However, recent mutagenesis studies support an alternate
model in which Ca D-E and Cb C-C’ loops of ab TCR interact
with CD33d and CD3g3, respectively, allowing TCR-CD33d inter-
actions to stabilize CD3g3 within the complex (Kuhns and Davis,
2007). In both models, the interaction of TCR-CD3 is suggested
to engender a rotational or piston-like displacement of the CD3
components upon Ag ligation that is transmitted through the
TCR to initiate signaling. Hence, a ligation-induced movement
in the A-B loop of Ca could potentially facilitate or guide this re-
arrangement or promote TCR dimerization, and is consistent
with a conformation-dependent model of T cell triggering.
Such a model would also be consistent with the ligand-induced
binding of Nck to the cytoplasmic tail of CD33 reflecting a change
in the TCR-CD3 conformation. Moreover, the role of this confor-
mational change does not preclude the importance of TCR-CD3
clustering and rearrangement of components within this
complex. Thus, the structural changes in the Ca domains of
liganded versus unliganded TCRs suggested to us that this
Ag-induced conformational change was a potential first step in
initiating T cell triggering through such a mechanism.
Molecularly Tagging the Ca A-B Loop
with Fluorochromes
Given that a mutagenesis approach is limited in its ability to
discriminate the role of CD3 components in TCR assembly and
transport versus their role in Ag-mediated signaling, we adopted
a more direct biochemical approach to address the central ques-
tion of whether Ag ligation of the TCR led to a dynamic and
discrete change in the conformation of theA-B loop in a biochem-
ical system. Site-directed fluorescence labeling (SDFL) permitted
examination of the conformational changewithin the TCRCa A-B
loop upon ligation with specific antigen, HLA-B8FLR. Many fluo-
rescent dyes are sensitive to water and their emission properties
change dramatically upon moving from an aqueous to
a nonaqueous environment, and such approaches have been
used previously in other biological systems to reveal conforma-
tional change and change of environment in protein structure
(Shatursky et al., 1999; Shepard et al., 1998). The dye we em-
ployed, N,N’-dimethyl-N-(iodoacetyl)-N’-(7-nitrobenz-2-oxa-1,
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and is uncharged, but possesses a polar characteristic that
enables it to be soluble in aqueous environment (Haugland,
1996). The emission of NBD is strongly quenched by water and
thus NBD fluorescence intensity increases when the dye moves
from aqueous to nonaqueous environment (Crowley et al.,
1994). To validate the suitability of this targeted NBD fluores-
cence-based approach in a TCR-pMHC system, we first intro-
duced a cysteine mutation in the CDR2b loop of the LC13 TCR
(Asn51b Cys) and labeled it with NBD (see Experimental Proce-
dures) (Figure 1E). We have previously shown that the LC13N51C
substitution does not affect the binding to HLA-B8FLR despite
Figure 1. Structures of the Liganded and
Unliganded-LC13 TCR
(A) The ‘‘open’’ conformation of LC13 TCR in
complex with HLA-B8 (PDB accession code
1MI5) (Kjer-Nielsen et al., 2002b). The MHC mole-
cule is represented as a cartoon and colored
green. The antigenic peptide is shown in stick
format with the carbon atoms colored magenta.
The heterodimeric TCR is colored by chain with
the a chain represented in blue and the b chain
in yellow. The variable and constant domains
within each chain are labeled Va,Vb and Ca,Cb,
respectively. The positions of the CDR loops and
the F-G loop are indicated. The position of the
A-B loop is indicated and highlighted in red. In
this ‘‘open’’ conformation, the A-B loop projects
away from the Cb domain.
(B) The ‘‘closed’’ conformation of LC13 TCR as
observed in the crystal structure of the unli-
ganded-TCR (PDB accession code 1KGC) (Kjer-
Nielsen et al., 2003). The figure is colored similarly
as in (A). The ‘‘closed’’ conformation of the A-B
loop is distinct from the ‘‘open’’ conformation in
that the A-B loop projects toward the Cb domain.
(C and D) Close-up view of the A-B loop, colored
red, in the open (C) and closed (D) conformations.
The side chains of the residues in the A-B loop are
displayed in stick format.
(E) Cartoon representation of the LC13 TCR struc-
ture colored by chain as detailed in (A). The posi-
tions of the residues mutated to cysteines to
enable the connection of the fluorescent probes
are indicated and depicted as red spheres. The
position of the cysteine mutations that introduce
a disulfide bond between the Ca and Cb domains
of the TCR, to produce the dsTCR, are labeled and
shown as green spheres.
the role of this region at the Ag interface
(Borgetal., 2005).The typical fluorescence
emission spectrum of LC13N51C-NBD
is shown (Figure 2A). Upon addition of
increasing amounts of the HLA-B8FLR,
the emission spectra showed a substan-
tial increase of fluorescence intensity at
535 nm (Figure 2A), suggesting a release
of water from the binding interface upon
ligation, which is consistent with the
biophysical analysis of the LC13-HLA-
B8FLR interaction (Ely et al., 2006).
However, there was no change in fluorescence intensity when
an irrelevant HLA-B8-restricted epitope, RAKFKQLL (HLA-
B8RAK), was used (Figure 2B), indicating that the change in
fluorescence intensity is attributable to specific binding to HLA-
B8FLR. Binding of HLA-B8FLR to LC13N51C-NBD showed a clear
dose dependence (Figure 2B). By fitting the data points, a
single-site hyperbolic function showed that equilibrium affinity
of the HLA-B8FLR-LC13N51C-NBD interaction was 4.16 ± 0.71 mM
(Figure 2B; Table 1). The TCR-pMHC affinity measured with the
NBD probe is nearly identical to that determined by monitoring
tryptophan fluorescence upon LC13-HLA-B8FLR ligation (Ely
et al., 2005) and closely matches the binding affinity as judgedImmunity 30, 777–788, June 19, 2009 ª2009 Elsevier Inc. 779
Immunity
T Cell Signaling and Conformational ChangeFigure 2. Change in Fluorescence of Intensity of NBD Attached to Cysteine Substituted at Position 51 and S133 of LC13
(A) The fluorescence emission of LC13N51C-NBD (solid line) when titrated with increasing concentration of HLA-B8FLR (16 mM) (dotted line).
(B) The change of fluorescence emission of LC13N51C-NBD at 535 nm at each concentration of HLA-B8-peptide complex was fitted to a single-site binding model
(solid line). The percentages of changes are means ± SE (n = 3).
(C) The change in fluorescence emission at 535 nm related as percentage (see Experimental Procedures) of LC13S133C-NBD is clearly present at 16 mMHLA-B8FLR
where there is little change in fluorescence in the presence of 16 mM HLA-B8RAK.
(D) The percentage change of fluorescence of LC13S133C-AEDANS and LC13S133C-NBD was fitted to a single-site binding model.bysurfaceplasmon resonance (Borg et al., 2005), suggesting that
this approach is well suited for probing other conformational
changes in the LC13 TCR (Table 1).
Conformational Movement of the A-B Loop
To establish whether HLA-B8FLR ligation to the LC13 TCR led to
a conformational change in the A-B loop, a serine at position 133
was substituted to cysteine (LC13S133C) and labeled with NBD
(LC13S133C-NBD) (Figure 1C). The fluorescence emission spec-
trum of LC13S133C-NBD is similar to that of LC13N51C-NBD, sug-
gesting that the NBD moiety is in an aqueous environment
(data not shown), which is consistent with the location of this
residue in the crystal structure (Figure 1C). The fluorescence
intensity of LC13S133C-NBD changed approximately 20% upon
the addition of increasing amounts of HLA-B8FLR (Figure 2C),
suggesting that the A-B loop changed conformation upon Ag
ligation. This change in fluorescence intensity was not observed
when similar concentrations of HLA-B8RAK were added,
revealing that the conformational change of the A-B loop occurs
only upon MHC-restricted Ag ligation (Figure 2C). In seven inde-
pendent experiments, there was clearly an Ag-dependent dose
change in fluorescence intensity of LC13S133C-NBD upon HLA-
B8FLR titration, as reported by the proposed conformational780 Immunity 30, 777–788, June 19, 2009 ª2009 Elsevier Inc.change in the A-B loop (Figure 2D). By fitting the data points to
a single site, hyperbolic function showed that equilibrium affinity
of LC13S133C-NBD interaction with HLA-B8FLR is Kd of 7.22 ±
3.54 mM, which is very similar to the affinity reported by
LC13N51C-NBD-positioned probe (Table 1), indicating that the
conformational change of the A-B loop is the result of Ag ligation.
The physio-chemical properties of some fluorescent probes
can occasionally lead to their burial into an environment
irrespective of conformation of the native unmodified protein
(Valeva et al., 1996). To discount this possibility in monitoring
the A-B loop movement, a different fluorescent probe, 5-((((2-io-
doacetyl)amino)ethyl)amino)naphthalene-1-sulfonic acid (IAE-
DANS), was attached to LC13S133C. AEDANS is an environmen-
tally sensitive probe, yet it has different physio-chemical
properties compared to NBD (Haugland, 1996). The typical
emission spectrum of LC13S133C-AEDANS (data not shown) shows
that AEDAN probe has a wavelength maximum at 480 nm. Upon
titration of increasing concentration of HLA-B8FLR against
LC13S133C-AEDANS, there was an approximately 25% change in
fluorescence intensity of the probe (data not shown). The calcu-
lation of the apparent equilibrium affinity constant (Kd) from the
change of fluorescence intensity was 8.95 ± 3.73 mM
(Figure 2D; Table 1), which matched closely to the Kd that was
Immunity
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flicting reports describing the propensity of TCRs to dimerize in
solution (Baker and Wiley, 2001; Deng et al., 2007), as well as
the observation of crystallographic TCR dimers (Tynan et al.,
2005), and our fluorescence-based observations may have
been attributable to such factors. To evaluate this possibility,
analytical ultracentrifugation (AUC) studies were undertaken on
the LC13 TCR in the nonligated and ligated state, which revealed
that the LC13 TCR and the LC13 TCR-HLA-B8FLR complex
remained monomeric in solution, even at very high protein
concentrations (data not shown). These studies indicated that
the conformational change in A-B loop in the LC13 TCR is
probe independent and is exquisitely linked to MHC-restricted
Ag ligation.
Movement within the Constant Domain Is Restricted
to the A-B Loop
To establish the extent of conformational change within the C
domain of the TCR upon Ag ligation, six additional single-site
cysteine substitutions were initially made within the constant
domain of the LC13 TCR, labeled with NBD, and assayed for
changes in fluorescence upon HLA-B8FLR binding (Figure 1E;
Table 1). Two of these residues in the A-B loop, Ser131a and
Ser134a (Figures 1C and 1D), exhibited a change in fluorescence
intensity upon HLA-B8FLR ligation of approximately 15% and
10%, respectively, and these changes were observed in multiple
experiments. Importantly, we determined the apparent equilib-
rium affinity constant of the proposed conformational change
for LC13S131C-NBD and LC13S134C-NBD to be 6.88 ± 1.99 mM
and 1.56 ± 0.40 mM, respectively (Figures 3A and 3B; Table 1).
This correlates well with the value obtained for LC13S133C-NBD.
Other positions within the constant domain that were tested for
movement were the F-G loop (Arg230b) and residues within
the Cb strand-A (Glu127b and Ala129b) and strand-G
(Ser239b) (Figure 1E). These sites were tested because they
Table 1. The Affinity of Interaction between TCR and Its Cognate
pMHC Determined by Change of Fluorescence Intensity
TCR Mutant KD (mM)
LC13 WT 12.5 (Borg et al., 2005)
LC13 WT 5.5 (Ely et al., 2005)
LC13N51C-NBD 4.16 ± 0.71
LC13S133C-NBD 7.22 ± 3.54
LC13S133C-AEDAN 8.95 ± 3.73
LC13S131C-NBD 6.88 ± 1.99








A6 WT 0.82 (Ding et al., 1999)
A6S133C-NBD 0.80 ± 0.22
ND, not determined.had previously been proposed to represent a docking site for
CD33g (Sun et al., 2001). There was no change in the fluores-
cence intensity spectra of LC13R230C-NBD, LC13A129C-NBD,
LC13E127C-NBD, or LC13S239C-NBD (Figure 3A) in the presence of
saturating concentration of HLA-B8FLR. We then extended this
analysis to three additional single-site cysteine substitutions,
namely at sites Ser170 (a chain, D-E loop), Ser151 (a chain, C
strand), and Ser139 (b-chain, A-B loop) in the LC13 TCR
(Figure 1E). These sites were chosen because they represented
candidate CD3 binding sites (Kuhns and Davis, 2007) and were
also located within potentially flexible regions of the C domain
of the TCR (Kjer-Nielsen et al., 2002b). There was no change in
the fluorescence intensity spectra of LC13S170C-NBD,
LC13S151C-NBD, and LC13S139Cb-NBD (Figure 3A) in the presence
of saturating concentration of HLA-B8FLR. These observations
are consistent with the Ag-induced conformational change being
restricted to the A-B loop of the Ca domain.
The A-B Loop Movement Is Reversible
If the A-B loop of the TCR acts as a dynamic switch upon Ag
ligation, then an important consideration is reversibility of the
conformational change upon removal of the Ag stimulation.
Hence, if the interaction between LC13S133C-NBD-HLA-B8FLR is
disrupted, such as in a competition assay with wild-type re-
combinant LC13 TCR, the conformation of A-B loop should
return, as judged by fluorescence measurements, to its original,
nonliganded state. As demonstrated, there is an approximately
20% change in fluorescence intensity in the emission spectrum
of LC13S133C-NBD when a saturating concentration of HLA-
B8FLR is added (Figure 3C). Upon adding 23 mM of unlabelled
LC13 to the LC13S133C-NBD-HLA-B8FLR sample, the fluorescence
intensity decreased to less than 5%, which was similar to the
unliganded LC13S133C-NBD emission spectrum (Figure 3C). The
apparent equilibrium Kd of this ‘‘reverse interaction’’ was 6.97 ±
1.75mM,which is similar to affinity determined for theAg-induced
movement of the A-B loop (Figure 3D; Table 1). Accordingly,
these observations show that the movement of the A-B loop is
reversible and is dictated by Ag ligation.
Inhibition of the A-B Loop Conformational Change
There are two potential pathways, which are not mutually exclu-
sive, that would enable pMHC-ligation at the Ag binding site to
be propagated distally to a conformational change in the A-B
loop of the TCR. First, given that the A-B loop is a continuation
of the CDR3a loop, conformational changes in the CDR3a loop
upon Ag ligation could be transmitted to the A-B loop where
they could impact on CD3 conformation (see Movie S1 in which
the crystal structure of the nonligated and ligated LC13 TCR is
compared). Second, a number of structural studies have shown
that there is a change in the juxtapositioning of the Va-Vb
domains upon Ag ligation and that such changes could be prop-
agated to the constant domain of the TCR, and indeed a recent
report has further highlighted this possibility (Ishizuka et al.,
2008). Definitively tracking such conformational changes can
be problematic, however, because the structures that are deter-
mined represent the static end-points, and as such we generally
lose any concept of the dynamics of this interaction, and thus the
established technology for mapping the pathway of conforma-
tional change is not yet established. Nevertheless, to establishImmunity 30, 777–788, June 19, 2009 ª2009 Elsevier Inc. 781
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domains to the C domains upon Ag ligation, we utilized a system
where a disulfide bond is introduced between the Ca and Cb
domains of the TCR (dsTCR), which has been shown to stabilize
TCRs without changing the affinity of TCRs for Ag (Boulter et al.,
2003). The dsLC13S133C was refolded and shown to contain the
engineered intermolecular disulfide bond (data not shown), to
exhibit identical chromatographic properties as LC13S133C, and
to be able to bind HLA-B8FLR with identical affinity to that of
the LC13 TCR-HLA-B8FLR interaction (data not shown). There
was minimal change in fluorescence intensity (<5%) when the
NBD-labeled TCR (dsLC13S133C-NBD) was incubated with HLA-
B8FLR (Figure 3E), suggesting that the intermolecular disulfide
bond between the constant domains inhibited conformational
movement of the A-B loop. This is consistent with the observa-
tions that Ag ligation propagates a signal from the V domains
to the C domains.
Figure 3. A-B LoopMovement Is Reversible
and Generic to Other TCRs
(A) The change in emission intensity of NBD at dif-
ferent positions in LC13 in the presence of 16 mM
HLA-B8FLR.
(B) The change of fluorescence intensity of
LC13S131C-NBD and LC13S134C-NBD was fitted to
a single-site model.
(C and D) The change in fluorescence intensity
when LC13S133C-NBD is saturated with HLA-B8FLR.
This fluorescence intensity was decreased by
titrating increasing concentrations of unlabelled
LC13. The percentage change of fluorescence
intensity LC13S131C-NBD + HLA-B8FLR + LC13
was fitted to a single-site model.
(E) The percentage change of fluorescence emis-
sion spectra of dsLC13S133C-NBD in the presence
of 16 mM HLA-B8FLR (n = 3) and A6S133C-NBD in
the presence of 4 mM HLA-A2TAX (n = 2) or HLA-
A2HSV (n = 3) (the control peptide from herpes
simplex virus, VLVDAIVRVA).
(F) The change of fluorescence of A6 was fitted to
a single-site binding model (solid line).
Movement of the A-B Loop
in Another TCR
In addition to the crystallographic
evidence pointing toward the generality
of movement in the A-B loop in other
TCRs upon Ag ligation, we examined
another TCR-pMHC system by using fluo-
rescence-based experiments to further
assess the dynamic conformational
changeof this loop.TheHLA-A2-restricted
A6 TCR was chosen for investigation
because it did not require an engineered
disulfide bond between the C domains
for refolding, and furthermore, the A6
TCR, and its interaction with HLA-A2
bound to the TAX peptide (HLA-A2TAX),
has been characterized extensively at the
structural and biophysical level (Ding
et al., 1998; Garboczi et al., 1996). Via the
same approach for the LC13 system, incubation of HLA-A2TAX
against A6S133C-NBD resulted in a 15% change in fluorescence
intensity of the probe (Figure 3E), whose apparent equilibrium
affinity constant for conformational change in the A-B loop
matched that of the affinity constant for Ag ligation (Kdz 1 mM)
(Figure 3F; Ding et al., 1998). Importantly, the A-B loop did not
change conformation when A6S133C-NBD was incubated with an
irrelevant HLA-A2-restricted peptide (Figures 3E and 3F). This
indicated that movement in the A-B loop upon Ag ligation is not
apropertyof a singleTCRand isaproperty that ispotentially appli-
cable to other TCRs.
Agonist versus Antagonist Recognition
Altered peptide ligands (APLs) can have markedly different
signaling outcomes compared to the authentic agonist ligand,
yet studies reported that there are few structural differences at
the TCR-pMHC interface when ligated to various APLs (Rudolph782 Immunity 30, 777–788, June 19, 2009 ª2009 Elsevier Inc.
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divergent signaling outcomes might reside in the differential
ability of the agonist or antagonist to trigger a conformational
change in the A-B loop. Indeed, close examination of the A6
TCR-HLAA2-APL structural studies indicates that the conforma-
tions of the A-B loop in the antagonist or weak agonist
complexes are consistent with the ‘‘closed’’ conformation (see
Supplemental Data; Ding et al., 1998, 1999). Recently, an APL,
FLRGRFGYL (HLA-B8ANT), has been described (Ely et al.,
2005) that acts as an antagonist for the LC13-HLA-B8FLR interac-
tion. The LC13-HLA-B8ANT interaction is of much weaker affinity
compared to the cognate interaction (Kd z 10 mM), and so we
aimed to establish whether the LC13-HLA-B8ANT interaction
led to a conformational change in the A-B loop. First, by using
the LC13N51C-NBD, we determined the affinity of the interaction
with HLA-B8ANT. The LC13N51C-NBD exhibited increase in inten-
sity when increasing concentrations of HLA-B8ANT was added
(data not shown). This behavior was identical to that observed
in the LC13N51C-NBD-HLA-B8FLR interaction (Figure 2B), suggest-
ing that the interaction between LC13N51C-NBD-HLA-B8ANT is
being monitored correctly. The affinity of this interaction as
calculated by the change of fluorescence was 24.09 ± 2.88 mM
(Figure 4B). When the same concentration range of HLA-B8ANT
A
B
Figure 4. The Interaction of Antagonist Ligand with LC13 Causes
No Movement in A-B Loop
(A) The percentage change of fluorescence intensity of LC13N51C-NBD and
LC13S133C-NBD at 60 mM HLA-B8ANT.
(B) The change of fluorescence intensity at 535 nm for LC13N51C-NBD and
LC13S133C-NBD is plotted against concentration of HLA-B8ANT and fitted to
a single-site model.was titrated against LC13S133C-NBD, there was no change in fluo-
rescence intensity at the wavelength maximum of 535 nm
(Figures 4A and 4B). These results indicate that the cognate
ligand and the antagonist ligand have a differential ability to
change the conformation of the A-B loop.
Impact of Mutations within the A-B Loop
The movement in the A-B loop of Ca is coincident with antigen-
specific TCR ligation, making it a possible candidate for sensing
antigen recognition and transmitting this to CD3. Therefore, we
introduced a number of mutations into the residues comprising
the A-B loop, and other regions of the constant domain, and
tested their impact on T cell activation in a cell-based system.
A CD8ab construct was first stably expressed by retroviral
gene transduction into the TCR-negative, human T cell line Ju-
rkat. The CD8+ Jurkat cells were then individually transduced
with retroviral expression constructs encoding the LC13 TCR
cDNA with the wild-type A-B loop 130DSKSSDK136 (AB-Wt);
deletion of the A-B loop residues SKSSDK (AB-Del); charge
reversals resulting in the A-B loop sequence DEEEEDK (AB-
Rev); lengthening of the A-B loop to contain the residues
DSKAAAAAAAASSDK (AB-Len); alanine substitution of the A-B
loop from the wild-type DSKSSDK to AAAAAAA (AB-Ala); with
potential disulfide bonding of the TCR constant domains by
introducing cysteine substitutions at Cys-a (Thr178Cys) and
Cys-b (Ser189Cys) (ab-Cys); and alanine substitution of the
wild-type residues MRSMDF to MAAAAF in the D-E loop of
Ca, previously documented to impair TCR-mediated T cell acti-
vation (DE-Ala) (Kuhns and Davis, 2007). It was evident from the
polyclonal transformants that expression of the LC13 TCR was
relatively inefficient for the receptors containing the A-B loop
deletion and charge reversal mutations (not shown), highlighting
the challenge in understanding the precise relationship between
CD3-TCR coexpression on the cell surface and mechanisms
underpinning TCR-CD3 triggering via a mutagenesis approach.
Nonetheless, after three rounds of cloning, CD8+ Jurkat T cells
expressing wild-type and mutant LC13 TCRs were closely
matched for levels of TCR expression as judged by staining
with HLA-B8FLR tetramers (Figure 5A). Antigen-specific activa-
tion of the Jurkat transformants was assayed by the upregulation
of cell surface CD69 2 hr after incubation with graded concentra-
tions of HLA-B8FLR tetramers. As shown in Figure 5B, the dose
dependence and maximal degree of CD69 upregulation varied
among the transduced cells, with wild-type LC13 Jurkat cells
showing the most efficient stimulation. As expected, Jurkat cells
expressing theDE-Alamutant showed a dose-dependent reduc-
tion in their T cell activation, whereas the LC13 TCR receptors
with engineered Cys residues in their constant domains also
demonstrated reduced activation. Although activation of the
ab-Cys mutant was only partially inhibited, this is consistent
with the impaired change in ligand-induced fluorescence inten-
sity of the dsLC13S133C recombinant TCR containing the engi-
neered intermolecular disulfide bond introduced between the
Ca and Cb domains of the TCR. Although we cannot confirm
the efficiency of the engineered intermolecular disulfide bond
in the Jurkat-expressed LC13 TCR, the findings suggest that
this bond does form naturally in the cell-based systempotentially
linking A-B loopmovement with reduced TCR signaling. The AB-
Del, AB-Rev, AB-Len, and AB-Ala loop mutations in LC13 TCRImmunity 30, 777–788, June 19, 2009 ª2009 Elsevier Inc. 783
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A
Figure 5. Functional Evidence that the Movement in the A-B Loop
of the TCR Ca Domain Is Involved in Early TCR Signaling
(A) Surface expression of wild-type and mutant LC13 TCRmolecules on retro-
virally transduced Jurkat cells. CD8+ Jurkat cells were individually transduced
with retroviral expression constructs encoding the LC13 TCR cDNA containing
the wild-type A-B loop (AB-Wt); a deletion of the A-B loop residues SKSSDK
(AB-Del); charge reversals resulting in the A-B loop sequence DEEEEDK
(AB-Rev); lengthening of the A-B loop to contain the residues DSKAAAAA
AAASSDK (AB-Len); alanine substitution of the A-B loop from the wild-type
DSKSSDK to AAAAAAA (AB-Ala); cysteine substitutions at Cys-a (T178C)
and Cys-b (S189C) (ab-Cys) to engender potential disulfide bonding of the
TCRconstant domains; andapolyalanine substitution of thewild-type residues
MRSMDF toMAAAAF in theD-E loop ofCa (DE-Ala), previously documented to
impair TCR-mediated T cell activation (Kuhns and Davis, 2007). Three succes-
sive rounds of cloning the CD8+ Jurkat T cells expressing wild-type andmutant
LC13 TCRs were necessary to match transformants as closely as possible for
levels of TCR expression. Cells were stained with HLA-B8FLR tetramer (PE
labeled) at room temperature for 45 min and analyzed by FACs. Staining with
HLA-B8FLR tetramer is shownas a log scale. Shaded histogram indicates back-
ground staining of the relevant cells in the absence of tetramer.
(B) Antigen-specific activation of Jurkat T cells transduced with parental LC13
andmutant TCRs described above. Jurkat transformants (23 105) were plated
in a U-bottom 96-well plate and HLA-B8FLR tetramer (APC labeled) was added
to the cells at the indicated final concentration thenmixed. After culture at 37C
for 2 hr, the plate was cooled on ice for 5 min and the cells were pelleted at
1200 rpm at 4C. The cells were stained with CD69 mAb (PE labeled) (30 min
on ice) and washed twice, and the mean channel fluorescence (MCF) of
CD69 staining was determined by flow cytometry. All Jurkat transformants
were activated after stimulation with OKT3 mAb (not shown). The experiment
was conducted twice with similar results.784 Immunity 30, 777–788, June 19, 2009 ª2009 Elsevier Inc.were all associated with markedly impaired upregulation of
CD69 after antigen-specific ligation (Figure 5B; Figure S3)
despite activation of these cells by stimulation with the CD3
mAb OKT3 (data not shown). Given the nature of the introduced
TCRmutations, the reduced T cell activation in the LC13mutants
may also arise from impaired TCR stability or assembly. There-
fore it is noteworthy that ligand-induced downregulation of
LC13 TCR was observed in all transformants after incubation
of Jurkat T cells with HLA-B8FLR tetramers at 37C (not shown),
implying that TCR clustering and internalization still occurred in
the mutant TCRs after Ag-specific ligation. Taken together, the
data are consistent with ligation-induced movement of the A-B
loop playing an important role in the events underpinning early
TCR signaling.
DISCUSSION
The mechanism by which receptor-ligand ligation results in
a signal being transmitted within the cell remains a key question
in a number of distinct biological systems. In the context of T cell
signaling, this extracellular-intracellular communication event is
even more intriguing because the TCR does not possess
signaling domains themselves; accordingly, pMHC ligation has
to be communicated to the CD3 signaling apparatus to which
the TCR is noncovalently associated. Our structural and SDFL
data demonstrate that Ag ligation leads to a discrete conforma-
tional change within the A-B loop of the constant domain of the
LC13 TCR, and this conformational change is MHC restricted
and coincident with that of Ag ligation, and is reversible upon
disengagement of the TCR. The conformational change in the
A-B loop of the TCR upon pMHC ligation although clearly evident
is also subtle and this is reflected in the changes in fluorescence
caused by Ag ligation. The fluorescence-based measurements
reported here are highly reproducible and statistically significant,
generate a dose-dependant response, and are well within the
range of other conformational changes measured with NBD as
a probe (Gether et al., 1997; Gibson et al., 1997; Jensen et al.,
2001). We have also observed this A-B loop conformational
change in two distinct, well-described TCR systems (namely
the LC13 and A6 TCR), and it will be important to test the further
generalities of these findings in other TCR systems, including
that of murine TCRs. Accordingly, at this stage it is unclear
whether all TCRs have a propensity for a similar conformational
change within the constant domain of the TCR, or whether it
represents a property of certain TCRs, such as immunodominant
TCRs for example (Ishizuka et al., 2008; Wang et al., 2008), or
whether it represents the vestiges of a primordial TCR signaling
mechanism.
Accordingly, our data are consistent with a conformational
model of T cell triggering mediated by antigen ligation of the
ab TCR. A conformational basis for T cell triggering is in agree-
ment with previous findings, where (1) ligation by TCR and
CD3 mAbs, monovalent Fab fragments, and pMHC ligands led
to a conformational change within the CD33 cytoplasmic domain
(Gil et al., 2002, 2005; Minguet et al., 2007; Risueno et al., 2005)
and in addition the conformation of the CD3zz chains are consid-
ered to be contingent on their immediate environment (Aivazian
and Stern, 2000); (2) T cell signaling occurs before the formation
of the immunological synapse and that a single pMHC agonist is
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triggering must be intrinsic to the CD3-TCR-pMHC interaction;
(3) furthermore, thermodynamic considerations indicated that
TCR-pMHC engagement induced a torque within the TCR
(Krogsgaard et al., 2003). Although studies have shown that clus-
tering of TCR-CD3 complexes play a role in T cell signaling, our
data reveal that conformational change within the constant
domain is independent of TCR dimerization, but it can neverthe-
less potentially promote TCR dimerization. It is possible that
clustering reflects a later evolutionary addition that serves to
amplify initial signaling. Although the precise geometry of the
TCR-CD3 complex is unknown and mutagenesis studies have
been ambiguous in defining TCR-CD3 interaction sites, the
movement of the A-B loop may also permit differential juxta-
positioning of the TCR-CD3 complex, thereby leading to a signal
being transmitted intracellularly. Ultimately to test this ‘‘molec-
ular switch’’ hypothesis, structural studies of complexes
between the TCR andCD3 components will be required to reveal
the detailed architecture of this interaction. It will also be useful to
undertake double-labeling experiments of the TCR with two
distinct fluorochromes so that the time dependence of the
increased fluorescence intensity of the A-B loop can be
measured with respect to pMHC binding.
Movement within the constant domain was not observed upon
binding to an antagonist pMHC ligand, which may permit
different signals to propagate intracellularly upon APL engage-
ment, which is consistent with partial agonists and antagonists
being unable to transmit a conformational change to the intracel-
lular domains of CD33 (Risueno et al., 2005). Moreover, although
the conformational changes at the TCR-pMHC interface may be
small when comparing cognate and APL complexes, the
differing molecular torque that has been observed to exist
between various TCR-pMHC complexes may serve as a means
to propagate a differing signal to the C domain of the TCR
(Krogsgaard et al., 2003). It will be of interest to establish whether
other receptors, including the gd TCR, the pre-Ta receptor, and
the B cell receptor, which adopt a similar architecture to that
of the ab TCR, transduce signals in a similar manner shown
for the ab TCR. Regardless, our findings provide a crucial link
between TCR ligation and distal conformational adjustments
that can potentially impact on the CD3 signaling molecules.
Importantly, lengthening, deleting, or substituting residues in
the A-B loop of the LC13 TCR is associated with markedly
impaired upregulation of CD69 after antigen-specific stimulation
in a T cell-based system. Modest impairment of signaling was
also observed in LC13 receptors with engineered Cys residues
in their constant domains, potentially forming an intermolecular
disulfide bond between the Ca and Cb domains, thus ‘‘fixing’’
the juxtaposition of the V regions within the TCR. Impairment in
signaling was at least comparable to that observed for mutations
in the D-E loop of the TCR a chain constant domain, previously
reported by others (Kuhns and Davis, 2007) to affect TCR
signaling. Collectively, the data provide supporting evidence
for the functional role of the A-B loop in the context of T cell trig-
gering. Even so, we are mindful that the A-B loop mutations may
also alter aspects of TCR stability and assembly affecting TCR
dimerization or TCR-CD3 juxta-positioning.
Our findings suggest a basis for understanding the earliest
events in TCR signaling in which antigen recognition by theTCR ab heterodimer potentially transmits Ag recognition to the
CD3 signalosome via a conformational change in the constant
domain of the TCR a chain.
EXPERIMENTAL PROCEDURES
Structural Data
For the structural comparisons of the A-B loop conformation, TCR structures,
nonliganded and pMHC ligated were downloaded from the PDB (see Table
S1). Only the structures of TCRs in which the complete ectodomains (namely
variable and constant domains) were analyzed are reported within this table.
Construction of TCR Mutants
The original LC13 TCR clone was prepared as previously described (Kjer-Niel-
sen et al., 2002b) and used as template to generate the TCR mutants by site-
directed mutagenesis (QuikChange; Stratagene, La Jolla, CA).
Expression and Purification of Recombinant Proteins
Soluble HLA-B8FLR and HLA-A2TAX complexes were prepared from E. coli
as described previously (Garboczi et al., 1992; Kjer-Nielsen et al., 2002a).
The refolded complexes were concentrated and purified by anion exchange
and gel filtration chromatography. The a and b chains of LC13 TCR were
expressed in BL21 (DE3) E. coli cells, refolded from inclusion bodies, and puri-
fied as previously described (Kjer-Nielsen et al., 2003). The structural integrity
of the refolded proteins was confirmed by apparent molecular weight of the
protein after size exclusion chromatography and by SDS-PAGE.
Modification of Cysteine-Substituted TCR with IANBD or IAEDANS
In a typical labeling reaction, 0.5 mg of TCR in 10 mM Tris-HCl (pH 7.4),
150 mM NaCl was labeled with 20-fold molar excess of IANBD or IAEDANS
(Molecular Probes, Eugene, OR) and incubated at 4C on rotating wheel for
16 hr. The labeled TCR was separated from free label by passing over a 5 ml
Desalting column (GE Healthcare) equilibrated in 10 mM Tris-HCl (pH 8.0),
150 mM NaCl, and 2 mM EDTA. The extent of the covalent reaction was esti-
mated with the extinction coefficient of 3478nm of 25,000 M
1 cm1 for NBD
and 3340nm of 5,700 M
1 cm1 for AEDANS (Haugland, 1996). The labeling
procedure resulted in incorporation of between 0.6 to 0.9 mol of NBD or
AEDANS per mol of TCR.
Spectrofluorometry Methods
Fluorescence emission spectra were recorded on a PerkinElmer Life Sciences
LS50B spectrofluorimeter by using a temperature-controlled cuvette at 25C
in a 1 cm path length quartz cell. Excitation and emission slits were set at
7.0 nm for all spectra, unless otherwise stated, and a scan speed of 10 nm/min
was used. Unless otherwise stated, 2 mM NBD-labeled TCR was excited
at 478 nm, with fluorescence emission spectra measured from 500 to
600 nm. Each concentration of MHC was added and allowed to mix for
1 min before recording of the spectra. The AEDANS-labeled TCR was excited
at 340 nm, with fluorescence emission spectra measured from 400 to 650 nm.
All of the samples tested had an absorbance of less than 0.1 at 535 nm in the
concentrations used excluding any ‘‘inner filter’’ effect in the fluorescence
experiments (data not shown). All changes in fluorescence spectra were
corrected for dilution effects. The percentage change in fluorescence was
calculated as
%DF = ðFI  FoÞ=FLC13N51 (1)
where FI is fluorescence intensity at x concentration of TCR-pMHC complex,
FO is the initial intenstity of the TCR, and FLC13N51 is themaximum fluorescence
change at 16 mM HLA-B8FLR. The means of three independent experiments
were fitted with Graphpad version 3.0 (GraphPad software).
Generation of CD8+ Jurkat Cells and LC13 Mutants
LC13 ab TCR cDNA was reverse transcribed from LC13 T cell clone RNA via
Superscript II (Invitrogen). LC13a (primers P1 and P2) and b chain (P3 and
P4) gene segments were amplified by PCR with the following primers: P1:
2A-LC13a-For:(EcoRI) 50- CGGAATTCGCTAGCCACCatgaagttggtgacaagc;
P2: hTRa.F2Agsg-Rev (BamHI, KasI/NarI) 50GGGCCCTGGGTTCTCTTCGACImmunity 30, 777–788, June 19, 2009 ª2009 Elsevier Inc. 785
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accacagccgcagcgt; P3: gsgF2A-LC13b-For (BamHI, KasI/NarI) 50GGATCC
GGCGCCACCAATTTCTCGCTGCTTAAGCAGGCCGGCGACGTCGAAGAGA
ACCCAGGGCCCatgggcaccaggctcctctgc; P4: hTRbetaC2-Rev: (XhoI) 50 CC
GCTCGAGCTGCAGctagcctctggaatcctttct.
CD8a cDNA was purchased from OriGene. CD8a primers (P5 and P6) and
CD8b primers (P7 and P8) were used to generate PCR products encoding the
CD8a and b chains: P5: CD8aEcoRI-For50cGAATTCcgtcctggggagcgcgtcat;
P6: CD8aXhoI-Rev 50 gCTCGAGcagggttagacgtatctcgc; P7: CD8bEcoRI-For
50cGAATTCggtgtcccgggcgcgccacg; P8: CD8bXhoI-Rev 50gCTCGAGtcgtgctc
gttactgaccga.
Amplicons were then cloned into pGEM-T Easy (Promega). These were veri-
fiedbysequencing,beforebeingtransferredseparately into the retroviral expres-
sion vector pMIG (denoted as pMIG-CD8a and pMIG-CD8b, respectively).
PCR products encoding LC13a and b chains were cloned into pGEM-T Easy
prior to cotransfer into the pMIG vector. The LC13a and LC13b gene segments
when expressed are predicted to be linked by a self-cleaving 2A peptide
(Szymczak et al., 2004), allowing for subsequent surface expression of the
LC13 ab TCR.
All the LC13 mutants were generated from the parental pGEM-LC13a-2A-
LC13b (AB-Wt) plasmid through site-directed mutagenesis. The four a chain
A-B loop mutants included deletion of the A-B loop residues SKSSDK (AB-
Del); charge reversals resulting in the A-B loop sequence DEEEEDK (AB-
Rev); lengthening of the A-B loop to contain the residuesDSKAAAAAAAASSDK
(AB-Len); and alanine substitution of theA-B loop from thewild-typeDSKSSDK
to AAAAAAA (AB-Ala). A mutant with potential disulphide bonding of the
TCR constant domains was created by introducing cysteine substitutions at
Cys-a (T178C) and Cys-b (S189C) (ab-Cys). A positive control signaling mutant
contained alanine substitution of the wild-type residues MRSMDF to MAAAAF
in the D-E loop of Ca, previously documented to impair TCR-mediated T cell
activation (ref) (DE-Ala). The mutagenesis primers were as follows: AB-Ala:
50CCTGCCGTGTACCAGCTGAGAgcagctgcagcagctgctgccTCTGTCTGCCTA
TTCACCGAT, resulting in the following A-B loop residues being altered from
DSKSSDK (wild-type) toAAAAAAA (mutant). AB-Del: 50gccgtgtaccagctgagaga
cTCTGTCTGCCTATTCACCGAT, resulting in the mutant A-B loop lacking the
residues: SKSSDK..; AB-Rev: 50GCCGTGTACCAGCTGAGAGACgaagagg
aagagGACAAGTCTGTCTGCCTATTCACC, resulting in the mutant A-B loop
containing the residues DEEEEDK; AB-Len: 50TACCAGCTGAGAgactctaaa
gcagctgcagcagctgctgccgcctccagtgacaagTCTGTCTG, resulting in the mutant
A-B loop containing the residues DSKAAAAAAAASSDK; DE-Ala: 50ACAGACA
AAACTGTGCTAGACATGgcagctgcagcaTTCAAGAGCAACAGTGCTGTG, re-
sulting in the D-E loop being altered from MRSMDF (wild-type) to MAAAAF
(mutant); ab-Cys: Cys-a(T178C): GTATATCACAGACAAAtgTGTGCTAGACAT
GAGG; Cys-b (S189C): CACAGTGGGGTCtGCACAGACCCGC.
Retroviral-Mediated Gene Transduction into Jurkat Cells
The plasmids pMIG-CD8a (4 mg) and pMIG-CD8b (4 mg) encoding the CD8a
and CD8b chains were individually combined with the packaging vectors
pPAM-E (4 mg) and pVSV-g (2 mg) and transfected into 106 293T cells in
a 10 cm dish as previously described with Fugene 6 (Roche) (Holst et al.,
2006). The transiently transfected 293T cells were further cultured for
5 days. During this time, the retrovirus-containing supernatant was collected
twice daily, combined, and used to transduce Jurkat (3T3.5) cells along with
polybrene (6 mg/ml). At the end of the transduction, Jurkat cells were analyzed
for expression of GFP and CD8ab (CD8b-PE staining) by fluorescence-acti-
vated cell sorting. Jurkat.CD8ab-positive cells were enriched by cell sorting
and were subsequently cloned by single-cell sorting by flow cytometry.
Similarly, the wild-type and mutant pMIG-LC13ab DNAs were individually
combined with the packaging vectors pPAM-E and pVSV-g and transfected
into 293T cells separately. The supernatant from each transfectionwas applied
to Jrt.CD8ab cells along with polybrene. After fluorescence-activated cell sort-
ing and single cell cloning, 7 cell clones were thus generated: Jrt.CD8ab.
LC13wt (AB-Wt), Jrt.CD8ab.LC13Scan (AB-Ala), Jrt.CD8ab.LC13Del (AB-
Del), Jrt.CD8ab.LC13DEscan (DE-Ala), Jrt.CD8ab.LC13CR (AB-Rev),
Jrt.CD8ab.LC13Len (AB-Len), and Jrt.CD8ab.LC13Cys (ab-Cys).
T Cell Activation Assays
23 105 Jrt.CD8ab.LC13 cells were cultured with or without antigen stimulation
for 2 hr at 37C. The antigen stimulation was carried out with HLA-B8 tetramers786 Immunity 30, 777–788, June 19, 2009 ª2009 Elsevier Inc.loaded with the FLRGRAYGL (FLR) peptide from Epstein Barr virus EBNA3A.
Control T cell stimulation was carried out with the CD3 mAb, OKT3. After incu-
bation with free ligand, the responder cells were pelleted and assayed for
CD69 upregulation by staining and visualization by a fluorescence-activated
cell sorter. T cell activation was measured by the increase in the mean channel
fluorescence (MCF) of CD69-stained Jurkat transformants.
SUPPLEMENTAL DATA
Supplemental Data include one figure, one table, and one movie and can be
found with this article online at http://www.cell.com/immunity/supplemental/
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